← All stocks

Stoke Therapeutics, Inc.

STOK Net selling

CIK 0001623526 #2049 in the set updated 17 Sep 2026

Bought (120 mo)

$94.98M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$167.24M

$11.56M on a plan · $24.59M straight out of an exercise

Sold at will

$131.09M

77 of 244 sales

Net

−$72.26M

−$36.11M against sales at will

By person

17 insiders · 263 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Skorpios Trust entity

10% owner

—

$122.58M (4)

−$122.58M

3,906,181

6.05%

$121.31M

−73.0%

ATP Life Science Ventures, L.P. entity

10% owner

$39.63M (2)

—

+$39.63M

0.0000%

$0.00

—

Harrison Seth Loring

Director

$39.63M (2)

—

+$39.63M

33,948,426

52.61%

$1.05B

+102.2%

RTW INVESTMENTS, LP entity

10% owner

$15.73M (6)

$471.63K (1)

+$15.25M

3,544,248

5.49%

$110.07M

—

Nash Huw M.

Chief Business Officer

—

$12.24M (48) scheduled

−$12.24M

0.0000%

$0.00

−100.0%

Kaye Edward M. MD

Director

—

$8.45M (31) scheduled

−$8.45M

124,557

0.1930%

$3.87M

—

Ticho Barry

CHIEF MEDICAL OFFICER

—

$6.88M (75) scheduled

−$6.88M

20,110

0.0312%

$624.55K

+709.3%

Tulipano Stephen J

Former CFO

—

$4.52M (12) scheduled

−$4.52M

20,746

0.0322%

$644.31K

+3,346%

Krainer Adrian R.

Director

—

$3.90M (5) scheduled

−$3.90M

283,302

0.4390%

$8.80M

−30.0%

Allan Jonathan

GENERAL COUNSEL & CORP SEC

—

$2.82M (37) scheduled

−$2.82M

21,225

0.0329%

$659.18K

+114.7%

Liau Gene

EVP Research & Preclinical Dev

—

$2.60M (11) scheduled

−$2.60M

21,351

0.0331%

$663.10K

—

TZIANABOS ARTHUR

Director

—

$1.70M (6) scheduled

−$1.70M

31,339

0.0486%

$973.29K

—

LEVIN ARTHUR A

Director

—

$782.11K (3) scheduled

−$782.11K

22,216

0.0344%

$689.96K

+23.6%

Leggett Thomas

Chief Financial Officer

—

$147.14K (5)

−$147.14K

10,172

0.0158%

$315.91K

—

Hoitt Jason

Chief Patient Officer

—

$119.31K (5)

−$119.31K

10,276

0.0159%

$319.14K

+157.7%

Walker Robin A.

Chief Legal Officer, CCO & Sec

—

$21.17K (1)

−$21.17K

0.0000%

$0.00

−100.0%

Redmile Group, LLC entity

10% owner

—

671,808

1.04%

$20.86M

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Kaye Edward M. MD

30 Dec 2024

CEO

Exercised, kept

35,000

$0.60

$21.00K

TZIANABOS ARTHUR

13 Feb 2024

Director

Exercised, kept

31,739

$2.19

$69.51K

Kaye Edward M. MD

27 Mar 2023

CEO

Exercised, kept

20,000

$0.60

$12.00K

Tulipano Stephen J

2 Jun 2022

CFO

Exercised, kept

11,160

$4.48

$50.00K

Kaye Edward M. MD

25 May 2022

CEO

Exercised, kept

15,000

$0.60

$9.00K

Kaye Edward M. MD

30 Dec 2020

CEO

Exercised, kept

10,000

$0.60

$6.00K

Liau Gene

31 Mar 2020

EVP Research & Preclinical Dev

Exercised, kept

7,500

$0.60

$4.50K

Showing 250 of 263 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 272

Amendments (4/A) skipped 3

Filings about a different issuer 0

Unreadable filings 0

Joint filings 13

Sales on a Rule 10b5-1 plan 71

Sales straight out of an exercise 96

Sales at will 77

Transactions with no price 0

Shares from compensation/vesting 53,171,597

Sales filed before the plan box existed 15

History held since 20 Jun 2019